Transcriptional Profiling of Peripheral Blood Mononuclear Cells in Pancreatic Cancer Patients Identifies Novel Genes with Potential Diagnostic Utility

Background It is well known that many malignancies, including pancreatic cancer (PC), possess the ability to evade the immune system by indirectly downregulating the mononuclear cell machinery necessary to launch an effective immune response. This knowledge, in conjunction with the fact that the trancriptome of peripheral blood mononuclear cells has been shown to be altered in the context of many diseases, including renal cell carcinoma, lead us to study if any such alteration in gene expression exists in PC as it may have diagnostic utility. Methods and Findings PBMC samples from 26 PC patients and 33 matched healthy controls were analyzed by whole genome cDNA microarray. Three hundred eighty-three genes were found to be significantly different between PC and healthy controls, with 65 having at least a 1.5 fold change in expression. Pathway analysis revealed that many of these genes fell into pathways responsible for hematopoietic differentiation, cytokine signaling, and natural killer (NK) cell and CD8+ T-cell cytotoxic response. Unsupervised hierarchical clustering analysis identified an eight-gene predictor set, consisting of SSBP2, Ube2b-rs1, CA5B, F5, TBC1D8, ANXA3, ARG1, and ADAMTS20, that could distinguish PC patients from healthy controls with an accuracy of 79% in a blinded subset of samples from treatment naïve patients, giving a sensitivity of 83% and a specificity of 75%. Conclusions In summary, we report the first in-depth comparison of global gene expression profiles of PBMCs between PC patients and healthy controls. We have also identified a gene predictor set that can potentially be developed further for use in diagnostic algorithms in PC. Future directions of this research should include analysis of PBMC expression profiles in patients with chronic pancreatitis as well as increasing the number of early-stage patients to assess the utility of PBMCs in the early diagnosis of PC.

[1]  E. Wurmbach,et al.  De-regulation of common housekeeping genes in hepatocellular carcinoma , 2007, BMC genomics.

[2]  Manuel Hidalgo,et al.  Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. , 2003, Cancer research.

[3]  S. Batra,et al.  Current status of molecular markers for early detection of sporadic pancreatic cancer. , 2011, Biochimica et biophysica acta.

[4]  E. Petricoin,et al.  Erratum: Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse (Cancer Cell (4) (437-450)) , 2004 .

[5]  E. Dougherty,et al.  Gene-expression profiles in hereditary breast cancer. , 2001, The New England journal of medicine.

[6]  Ash A. Alizadeh,et al.  Individuality and variation in gene expression patterns in human blood , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[7]  W. Steinberg.  The clinical utility of the CA 19-9 tumor-associated antigen. , 1990, The American journal of gastroenterology.

[8]  M. Tempero,et al.  AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. , 1999, Gastroenterology.

[9]  Lynette M. Smith,et al.  Effects of Thymoquinone in the Expression of Mucin 4 in Pancreatic Cancer Cells: Implications for the Development of Novel Cancer Therapies , 2010, Molecular Cancer Therapeutics.

[10]  C. N. Hansen,et al.  Expression of CPEB, GAPDH and U6snRNA in cervical and ovarian tissue during cancer development , 2009, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[11]  D. Tan,et al.  Diagnostic and prognostic biomarkers in pancreatic carcinoma. , 2009, International journal of clinical and experimental pathology.

[12]  Yingdong Zhao,et al.  Analysis of Gene Expression Data Using BRB-Array Tools , 2007, Cancer informatics.

[13]  C. Boland,et al.  American Gastroenterological Association. Our new president--Jon I. Isenberg, M.D. , 2001, Gastroenterology.

[14]  M. Manns,et al.  Increase in frequency of myeloid‐derived suppressor cells in mice with spontaneous pancreatic carcinoma , 2009, Immunology.

[15]  M. Goggins.  Molecular markers of early pancreatic cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  T. Poggio,et al.  Multiclass cancer diagnosis using tumor gene expression signatures , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[17]  David A. Tuveson,et al.  Maximizing mouse cancer models , 2007, Nature Reviews Cancer.

[18]  M. Oka,et al.  Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. , 2007, International journal of oncology.

[19]  Wei-Yuan Zhang,et al.  Gene expression profiling of maternal blood in early onset severe preeclampsia: identification of novel biomarkers , 2009, Journal of perinatal medicine.

[20]  Nan Hu,et al.  Genome-wide association study in esophageal cancer using GeneChip mapping 10K array. , 2005, Cancer research.

[21]  M. Zenilman,et al.  Use of gene expression profiles in cells of peripheral blood to identify new molecular markers of acute pancreatitis. , 2008, Archives of surgery.

[22]  M. Feldmann,et al.  Molecular Profile of Peripheral Blood Mononuclear Cells from Patients with Rheumatoid Arthritis , 2007, Molecular medicine.

[23]  Syed Mohsin,et al.  Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer , 2003, The Lancet.

[24]  Manuel Hidalgo,et al.  Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  D. Pleskow,et al.  Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. , 1989, Annals of internal medicine.

[26]  Y. Tian,et al.  The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[27]  J. Talmadge.  Pathways Mediating the Expansion and Immunosuppressive Activity of Myeloid-Derived Suppressor Cells and Their Relevance to Cancer Therapy , 2007, Clinical Cancer Research.

[28]  Tumour markers in gastrointestinal cancers--EGTM recommendations. European Group on Tumour Markers. , 1999, Anticancer research.

[29]  E. Petricoin,et al.  Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. , 2003, Cancer cell.

[30]  J. Hoheisel,et al.  DNA Microarray Analysis of Pancreatic Malignancies , 2004, Pancreatology.

[31]  A. Pinchera,et al.  Fine-needle aspiration of thyroid nodules: proteomic analysis to identify cancer biomarkers. , 2008, Journal of proteome research.